Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of the fiscal period ended Saturday, December 31, 2022.
Reported annual fiscal-period values; no daily interpolation.
PEG RATIO
N/A
PEG RATIO AVG TTM
4.71
PEG RATIO AVG 3Y
3.26
PEG RATIO AVG 5Y
2.99
PEG RATIO AVG 10Y
1.90
PEG RATIO AVG 15Y
N/A
PEG RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$364.02B
PEG Ratio
N/A
TTM Avg
1.64
3Y Avg
1.82
5Y Avg
1.66
Market Cap
$224.09B
PEG Ratio
4.54
TTM Avg
4.59
3Y Avg
4.59
5Y Avg
2.78
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $439.68B | N/A | 4.71 | 3.26 | 2.99 |
| Merck & Co., Inc. (MRK)vs › | $366.74B | 1.81 | 0.91 | 1.19 | 0.93 |
| UnitedHealth Group Incorporated (UNH)vs › | $364.02B | N/A | 1.64 | 1.82 | 1.66 |
| Roche Holding AG (RHHBY)vs › | $344.74B | 0.36 | 0.36 | 0.36 | 1.72 |
| AstraZeneca PLC (AZN)vs › | $248.20B | 0.59 | 1.04 | 0.64 | 0.57 |
| Johnson & Johnson (JNJ)vs › | $648.55B | 0.21 | 0.21 | 0.16 | 0.28 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.09B | 4.54 | 4.59 | 4.59 | 2.78 |
| Amgen Inc. (AMGN)vs › | $212.20B | 0.26 | 0.26 | 2.94 | 2.94 |
| Novo Nordisk A/S (NVO)vs › | $200.54B | 8.16 | 4.72 | 3.07 | 2.83 |
| Abbott Laboratories (ABT)vs › | $182.59B | 4.24 | 0.11 | 0.36 | 0.88 |
PEG Ratio
N/A
P/E Ratio
72.3
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2022-12-31 | 9.26 |
| 2021-12-31 | 0.15 |
| 2019-12-31 | 0.38 |
| 2018-12-31 | 2.18 |
| 2016-12-31 | 1.08 |
| 2015-12-31 | 0.10 |
| 2012-12-31 | 0.18 |
